ClinicalTrials.gg
Not yet recruitingNCT07344168Updated Mar 13, 2026

EndoArt® Implantation in Subjects With Chronic Corneal Edema - US Study

An interventional study of The EndoArt® (Corneal Artificial Endothelial layer) in Corneal Edema, sponsored by Eye-yon Medical. Not yet recruiting. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Eye-yon Medical · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
35 Years to 85 Years
Sex
All
01

Study summary

The EndoArt® device is intended to treat patients with chronic corneal edema due to endothelial dysfunction, in whom prior multiple keratoplasty (EK/PK) have failed, and who are not reasonable candidates for any form of corneal transplant, including penetrating keratoplasty.

The EndoArt® (Corneal Artificial Endothelial layer) is a permanent synthetic implant. It is made of a clear, transparent, foldable, biologically compatible hydrophilic copolymer. The device serves as an inert physical barrier, blocking the ingress of fluid from the Anterior Chamber (AC) into the cornea.

Read the detailed description

The study is a prospective, multi-center, open-label, single arm pivotal clinical investigation. The objective is to evaluate the safety and effectiveness of EndoArt® implantation in subjects with chronic corneal edema, in whom multiple prior keratoplasty (EK/PK) procedures have failed, and who are not reasonable candidates for any form of corneal transplant, including penetrating keratoplasty.

Safety will be assessed by evaluating the rate of any device related SAE occurred through the 12-month follow-up period.

The primary effectiveness endpoint is the proportion of subjects achieving an improvement in visual acuity of at least 0.20 LogMAR for subjects with baseline BCVA better than 1.30 LogMAR, or an improvement to at least 1.30 LogMAR for subjects with baseline BCVA equal or worse than 1.30 LogMAR, at 12 months postoperatively.

Subjects with chronic corneal edema, in whom multiple prior keratoplasty (EK/PK) have failed, and who are not reasonable candidates for any form of corneal transplant, including penetrating keratoplasty will be the study target population.

Only subjects who have signed the informed consent form and meet all the eligibility criteria listed below will be qualified for enrollment. The study will include a total of 123 surgically treated subjects. This clinical investigation will be conducted in a maximum of fifteen (20) clinical sites in the USA.

02

Conditions studied

  • Corneal Edema

Browse trials for

Keywords

  • Corneal edema
  • Chronic corneal edema
  • Artificial Endothelial layer
  • EndoArt
  • Failed keratoplasty
  • Human tissue corneal transplantation failure
  • Failed DSEK
  • Failed DMEK
03

In context

Corneal Edema

39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.

This study's planned enrollment of 123 is above the median of 52 across 31 interventional studies indexed under Corneal Edema.

Browse Corneal Edema studies →

Lead sponsor

Eye-yon Medical is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 30-85 years of age.
  2. Have chronic corneal edema (lasting at least 3 months) and have experienced at least 3 prior keratoplasty (EK/PK) failures.
  3. Is not a reasonable candidate for any form of corneal transplant, including penetrating keratoplasty.
  4. CCT of 650-1200 μm, not including DSAEK thickness.

    * In cases where the treated eye has undergone PKP, or if the corneal thickness of the contralateral eye cannot be measured (e.g., monocular patient, or if the contralateral eye has corneal edema or a history of PKP), the CCT of the study eye must be between 700-1200 μm.

  5. Pseudophakia
  6. Cornea WTW between 10-13 mm
  7. IOP \<20 mmHg and IOP≥8 mmHg
  8. BCVA of the study eye equal or worse than 0.50 LogMAR and up to 2.40 LogMAR (Hand motion is between 2.20-2.40 LogMAR).
  9. Must have better visual acuity in the contralateral eye, which must be at least 0.20 LogMAR better than the treated eye and have a visual acuity of at least 1.00 LogMAR.
  10. Central general clarity grade ≥2 (See Table 14. Central general clarity grading)
  11. Willing and able to understand and sign prior to any study-related procedure.
  12. Willing and able to follow study instructions (e.g., to lay on one's back for at least 4 hours post op.), able to self-administer or have caregiver available to administer eyedrops as required by the protocol for the duration of the study, and able to attend study visits/assessments for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. No light perception or light perception.
  2. Opaque scar in the visual axis that is indicated for PKP.
  3. Irregular posterior cornea (e.g. post trauma) in the 6.5 mm central part of the cornea (EndoArt® diameter).
  4. Current infection of the cornea.
  5. Central Band keratopathy and/or limbal stem cell deficiency.
  6. Diagnosis of: Sjogren's Syndrome, .
  7. PUK (peripheral ulcerative keratitis)
  8. Phthisis bulbi or subject is at high risk of developing phthisis (Hypothony).
  9. History of corneal refractive surgery: LASIK, PRK, SMILE, Epi-keratoplasty (or any anterior lamellar keratoplasty, inlays) and Radial Keratotomy (RK).
  10. Severe corneal distortion e.g.: keratoconus, pellucid marginal degeneration or keratoglobus (not relevant post PKP).
  11. Subject with medically uncontrolled intra ocular pressure, which requires surgical intervention.
  12. Aphakia.
  13. Active inflammation, or active, recurrent, or Chronic Uveitis
  14. Dislocation or partial dislocation of the IOL.
  15. Have large iris defect (more than 90 degrees) which could compromise intraoperative air bubble formation, excluding inferior defect.
  16. Severe ptosis (middle of pupil or covering the pupil entirely).
  17. Subject receiving regular intravitreal injection.
  18. History of persistent/ recurrent corneal erosion or persistent epithelial defect with difficulties in epithelial re-growth (erosion more than 2 months).
  19. History of ocular herpetic keratitis
  20. Current retinal detachments
  21. Advanced optic nerve cupping (defined as a cup-disc ratio of 0.9 or greater).
  22. Posterior segment masses or other acute significant posterior segment pathology (e.g., active age-related macular degeneration or chronic cystoid macular edema).
  23. Afferent Pupillary Defect (APD)
  24. Fellow eye CCT \< 500 µm
  25. Any other acute ocular condition
  26. Bilateral implantation of the EndoArt®
  27. Posterior vitrectomy (anterior vitrectomy is allowed)
  28. Subjects with mental impairment
  29. Subject with history of spontaneous corneal perforations.
  30. Pregnant or lactating women, or with childbirth plans during the clinical trial
  31. Currently participating or have participated in an study, other than this study, within the past 60 days.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    EndoArt® Artificial Endothelial Layer

    Implantation of the EndoArt (Artificial Endothelial Layer)

    Device: The EndoArt® (Corneal Artificial Endothelial layer)

Interventions

  • DeviceThe EndoArt® (Corneal Artificial Endothelial layer)

    Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSEK/DMEK

06

What researchers measure

Primary outcomes

  1. The rate of any device related SAE

    SAEs may include, but are not limited to, e.g., secondary surgical intervention, severe infectious keratitis requiring hospitalization, and corneal perforation

    Time frame: 12 months

  2. Improvement in visual acuity as measured by BCVA

    The proportion of subjects achieving a change in visual acuity of at least 0.20 LogMAR for subjects with baseline BCVA better than 1.30 LogMAR, or a visual acuity of 1.30 LogMAR or better at 12 months postoperatively for subjects with baseline BCVA of 1.30 LogMAR or worse

    Time frame: 12 months

Secondary outcomes

  1. All AE rate

    Rate of each AE

    Time frame: 12 months

  2. BCVA Success rate

    BCVA Success rate of bad Vision Population (Baseline BCVA ≥ 1.30 LogMAR)

    Time frame: 12 months

  3. CCT

    Change in central corneal thickness as measured by OCT from baseline to 12 months

    Time frame: 12 months

  4. Change in manifest refraction

    The change in manifest refraction

    Time frame: 12 months

  5. Corneal clarity

    Change in central general clarity grading score (using a scale of 0-normal to 4-severe)

    Time frame: 12 months

  6. Distribution of BCVA change

    BCVA change

    Time frame: 12 months

  7. Distribution of BCVA outcomes (using FrACT10)

    BCVA outcomes

    Time frame: 12 months

  8. BCVA Success rate

    BCVA Success rate of good Vision Population (Baseline BCVA \< 1.30 LogMAR)

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344168
Lead sponsor
Eye-yon Medical
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Mar 13, 2026

Study contacts

Limor Kuznits
Contact
limor@eye-yon.com
+972-73-7803607
Tamar Shaked
Contact
Tamar@eye-yon.com
+972-73-7803607

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion